SAGESage TherapeuticsSAGE info
$5.67info-3.74%24h
Global rank14103
Market cap$340.39M
Change 7d-0.18%
YTD Performance-73.44%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Sage Therapeutics (SAGE) Stock Overview

    Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

    SAGE Stock Information

    Symbol
    SAGE
    Address
    215 First StreetCambridge, MA 02142United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.sagerx.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    617 299 8380

    Sage Therapeutics (SAGE) Price Chart

    -
    Value:-

    Sage Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $5.67
    N/A
    Market Cap
    $340.39M
    N/A
    Shares Outstanding
    60.03M
    N/A
    Employees
    689.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org